

Alexander Drilon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/864461/publications.pdf>

Version: 2024-02-01

63
papers

7,371
citations

101543

36
h-index

114465

63
g-index

64
all docs

64
docs citations

64
times ranked

7109
citing authors

#	ARTICLE	IF	CITATIONS
1	NTRK fusion-positive cancers and TRK inhibitor therapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 731-747.	27.6	975
2	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discovery</i> , 2017, 7, 400-409.	9.4	647
3	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology</i> , The, 2020, 21, 531-540.	10.7	608
4	NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. <i>Modern Pathology</i> , 2020, 33, 38-46.	5.5	373
5	Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2016, 17, 1653-1660.	10.7	365
6	Selective RET kinase inhibition for patients with RET-altered cancers. <i>Annals of Oncology</i> , 2018, 29, 1869-1876.	1.2	304
7	Targeting MET in Lung Cancer: Will Expectations Finally Be MET?. <i>Journal of Thoracic Oncology</i> , 2017, 12, 15-26.	1.1	299
8	High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. <i>Clinical Cancer Research</i> , 2019, 25, 4712-4722.	7.0	292
9	Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. <i>Nature Medicine</i> , 2020, 26, 47-51.	30.7	255
10	Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. <i>Clinical Cancer Research</i> , 2015, 21, 3631-3639.	7.0	236
11	PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. <i>Annals of Oncology</i> , 2018, 29, 2085-2091.	1.2	221
12	MET-dependent solid tumours – molecular diagnosis and targeted therapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 569-587.	27.6	165
13	Response to ERBB3-Directed Targeted Therapy in <i>NRG1</i> -Rearranged Cancers. <i>Cancer Discovery</i> , 2018, 8, 686-695.	9.4	149
14	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. <i>Nature Medicine</i> , 2019, 25, 1422-1427.	30.7	144
15	Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1595-1601.	1.1	137
16	ROS1-dependent cancers – biology, diagnostics and therapeutics. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 35-55.	27.6	134
17	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. <i>Nature Medicine</i> , 2019, 25, 1839-1842.	30.7	122
18	Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. <i>Cancer Research</i> , 2019, 79, 1047-1053.	0.9	112

#	ARTICLE	IF	CITATIONS
19	TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. <i>Clinical Cancer Research</i> , 2020, 26, 1624-1632.	7.0	103
20	Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. <i>Annals of Oncology</i> , 2016, 27, 1286-1291.	1.2	92
21	A Phase I/II Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. <i>Cancer Discovery</i> , 2019, 9, 384-395.	9.4	88
22	Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib. <i>Clinical Cancer Research</i> , 2021, 27, 34-42.	7.0	87
23	Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of <i>NTRK</i>, <i>ROS1</i>, and <i>ALK</i> fusion-positive solid tumors. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1247-1252.	2.0	84
24	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 2698-2709.	1.6	83
25	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1253-1263.	1.6	74
26	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <i>NTRK</i> Fusion-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1302-1312.	7.0	74
27	Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. <i>Neuro-Oncology</i> , 2022, 24, 997-1007.	1.2	72
28	Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3287-3295.	7.0	66
29	Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4160-4167.	7.0	64
30	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2899-2909.	7.0	62
31	Antitumor Activity of RXDX-105 in Multiple Cancer Types with <i>RET</i> Rearrangements or Mutations. <i>Clinical Cancer Research</i> , 2017, 23, 2981-2990.	7.0	61
32	Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by <i>NRG1</i> Gene Rearrangements. <i>Cancer Discovery</i> , 2022, 12, 1233-1247.	9.4	60
33	Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. <i>Nature Medicine</i> , 2022, 28, 946-957.	30.7	50
34	The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. <i>Nature Communications</i> , 2022, 13, 1450.	12.8	47
35	Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes. <i>Clinical Cancer Research</i> , 2021, 27, 4066-4076.	7.0	45
36	<i>MET</i> Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life. <i>Clinical Cancer Research</i> , 2016, 22, 2832-2834.	7.0	44

#	ARTICLE	IF	CITATIONS
37	Progresses Toward Precision Medicine in <i>RET</i> -altered Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 6102-6111.	7.0	39
38	A Performance Comparison of Commonly Used Assays to Detect RET Fusions. <i>Clinical Cancer Research</i> , 2021, 27, 1316-1328.	7.0	39
39	Characterization of on-target adverse events caused by TRK inhibitor therapy. <i>Annals of Oncology</i> , 2020, 31, 1207-1215.	1.2	39
40	MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by <i>ROS1</i> Fusions. <i>Clinical Cancer Research</i> , 2020, 26, 2932-2945.	7.0	35
41	<i>MET</i> Exon 14-altered Lung Cancers and MET Inhibitor Resistance. <i>Clinical Cancer Research</i> , 2021, 27, 799-806.	7.0	35
42	Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2446-2456.	4.1	35
43	NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors. <i>Communications Biology</i> , 2020, 3, 776.	4.4	34
44	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. <i>Cancer Discovery</i> , 2021, 11, 126-141.	9.4	34
45	Clinicopathologic Features and Response to Therapy of <i>NRG1</i> Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. <i>Journal of Clinical Oncology</i> , 2021, 39, 2791-2802.	1.6	32
46	The METeoric rise of MET in lung cancer. <i>Cancer</i> , 2020, 126, 4826-4837.	4.1	29
47	Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. <i>JCO Precision Oncology</i> , 2022, 6, e2100418.	3.0	29
48	A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5202-5211.	7.0	26
49	NTRK fusions in lung cancer: From biology to therapy. <i>Lung Cancer</i> , 2021, 161, 108-113.	2.0	24
50	<i>KRAS</i> G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2604-2612.	7.0	20
51	NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. <i>British Journal of Cancer</i> , 2022, 126, 514-520.	6.4	19
52	Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. <i>Npj Precision Oncology</i> , 2022, 6, 13.	5.4	18
53	Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. <i>Oncologist</i> , 2022, , .	3.7	18
54	TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults. <i>Cancer Genetics</i> , 2022, 264-265, 33-39.	0.4	16

#	ARTICLE	IF	CITATIONS
55	Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program. <i>Cancer</i> , 2016, 122, 1228-1237.	4.1	10
56	CT features of HER2-mutant lung adenocarcinomas. <i>Clinical Imaging</i> , 2018, 51, 279-283.	1.5	9
57	Spectrum of <i>BRAF</i> Mutations and Gene Rearrangements in Ovarian Serous Carcinoma. <i>JCO Precision Oncology</i> , 2021, 5, 1480-1492.	3.0	8
58	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. <i>British Journal of Cancer</i> , 2022, 126, 889-898.	6.4	8
59	ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series. <i>JCO Precision Oncology</i> , 2022, 6, e2200015.	3.0	8
60	<i>MYC</i> Promotes Tyrosine Kinase Inhibitor Resistance in <i>ROS1</i> -Fusion-Positive Lung Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 722-734.	3.4	6
61	Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase. <i>JCO Precision Oncology</i> , 2022, , .	3.0	5
62	Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2020, 21, e25-e29.	2.6	1
63	An Ascendant Challenge: Central Nervous System Metastases in <i>ALK</i> + Lung Cancers. <i>Clinical Cancer Research</i> , 2022, 28, 2477-2479.	7.0	1